News


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: News

News

Our news team covers important developments in Alzheimer research and related fields of biomedicine, basic science and technology. Updates on drug development are listed under Drug News. Archived stories can be retrieved through our News search interface. All stories are based on original reporting and writing by our news team unless otherwise indicated.

RESEARCH NEWS

DRUG NEWS

CONFERENCE NEWS

Note: We strive to include all Alzheimer-relevant basic and clinical research citations in our database, and to provide balanced reports of major developments in our News department. Any omissions are unintended, and we very much appreciated being notified about them. Contact us.






			Announcing Alzheimer's Research & Therapy, a new online peer-reviewed journal which publishes open access research articles of outstanding quality in Alzheimer's research.









			Should the FDA be allowed to use data from overseas clinical trials?

			Absolutely, we are running out of viable subjects in the U.S.
			9

			Yes, so long as the data is reliable
			31

			No, the trials are not as rigorous
			3

			No, the data should be repeated in the U.S.
			5

			No, the drug sponsors are just trying to cut corners
			3

			Responses: 51







			Archived Polls







			Check out our ongoing Forum Webinar: Who Should Use the New Diagnostic Guidelines? The Debate Continues. See our recent Webinar: Adding Dynamics and Nuance to Alzheimerʼs Staging, held 5 January 2012. Check out our ongoing Forum Webinar: Evolution of AD Trials.





			Related Links

			NIA news site Alzheimer's Association ADDF/ISOA